Maternal Obesity in Pregnancy, Gestational Weight Gain, and Risk of Childhood Asthma

abstract

BACKGROUND AND OBJECTIVE: Environmental or lifestyle exposures in utero may influence the development of childhood asthma. In this meta-analysis, we aimed to assess whether maternal obesity in pregnancy (MOP) or increased maternal gestational weight gain (GWG) increased the risk of asthma in offspring.

METHODS: We included all observational studies published until October 2013 in PubMed, Embase, CINAHL, Scopus, The Cochrane Database, and Ovid. Random effects models with inverse variance weights were used to calculate pooled risk estimates.

RESULTS: Fourteen studies were included (N = 108,321 mother-child pairs). Twelve studies reported maternal obesity, and 5 reported GWG. Age of children was 14 months to 16 years. MOP was associated with higher odds of asthma or wheeze ever (OR = 1.31; 95% confidence interval [CI], 1.16–1.49) or current (OR = 1.21; 95% CI, 1.07–1.37); each 1-kg/m² increase in maternal BMI was associated with a 2% to 3% increase in the odds of childhood asthma. High GWG was associated with higher odds of asthma or wheeze ever (OR = 1.16; 95% CI, 1.001–1.34). Maternal underweight and low GWG were not associated with childhood asthma or wheeze. Meta-regression showed a negative association of borderline significance for maternal asthma history (P = .07). The significant heterogeneity among existing studies indicates a need for standardized approaches to future studies on the topic.

CONCLUSIONS: MOP and high GWG are associated with an elevated risk of childhood asthma; this finding may be particularly significant for mothers without asthma history. Prospective randomized trials of maternal weight management are needed.
Obesity is a major public health problem, affecting >35% of the adult population in the United States and complicating up to 20% of pregnancies in this country. Maternal obesity is defined as a BMI ≥30 kg/m², and maternal overweight is defined as a BMI between 25 and 29.9 kg/m². Maternal obesity is further stratified into classes: class I (BMI 30–34.9), class II (BMI 35–39.9), and class III (BMI ≥40). Maternal obesity in pregnancy (MOP) has been associated with adverse pregnancy outcomes, including hypertensive disorders of pregnancy, gestational diabetes, and need for operative delivery. Maternal obesity also has a significant impact on fetal development, the neonatal period, and overall childhood development. It has been associated with an elevated incidence of fetal neural tube defects such as spina bifida and anencephaly. Moreover, higher gestational weight gain (GWG) increases the risk of small for gestational age and of iatrogenic preterm birth.

In recent years, there has been growing interest on how in utero exposures predispose infants to diseases throughout the life span. For example, British epidemiologist David Barker reported that people with a history of low birth weight were at elevated risk of coronary artery disease later in life and, in what came to be known as the Barker hypothesis, theorized that the origins of complex diseases may stem from intrauterine exposures. Thus, MOP may significantly affect life ex utero for years to come. Given the substantial impact of maternal obesity on not only maternal but also fetal and neonatal outcomes, in 2009 the Institute of Medicine recommended that obese women limit their GWG to between 11 and 20 pounds.

Asthma, a complex disease that affects ~7 million children in the United States, can result from interactions between hereditary and environmental factors beginning in utero. For example, maternal smoking during pregnancy increases the risk of asthma in offspring and may hinder age-dependent improvement in airway hyperreactivity among children with asthma. Along these lines, there is growing evidence that MOP or high GWG is associated with elevated risk of asthma or wheeze (a symptom of asthma) in offspring. It is thought that in utero exposure to different dietary patterns or to the proinflammatory milieu of obesity may affect fetal immune or pulmonary development, thus leading to asthma. Therefore, the aims of this meta-analysis were to quantitatively estimate the effect of MOP or GWG on childhood asthma or wheeze, to generate a pooled analysis of studies available in the literature, and to explore factors that may modify the effect of MOP on childhood asthma.

METHODS

We prospectively registered the protocol for this meta-analysis in PROSPERO on September 5, 2013: http://www.crd.york.ac.uk/PROSPERO/display_record.asp?id=CRD42013005490.

Sources and Study Selection

We searched PubMed, Embase, Cumulative Index to Nursing and Allied Health Literature, Scopus, the Cochrane Database, and Ovid for observational studies evaluating the association between MOP or GWG and asthma or wheeze in childhood, published up to October 2013. Initial inclusion criteria were as follows:

- Population: Children in whom outcomes were measured between birth and <18 years of age. Mothers in whom BMI at the beginning of pregnancy was ascertained directly or by report at some point during pregnancy or whose GWG was ascertained directly or by report in the third trimester of pregnancy.
- Outcomes: Wheeze or asthma during childhood, determined by report, doctor’s diagnosis, medical record review, or evaluation by the study team. When >1 time point for such assessment existed, only the latest point available was included.

Two authors (E.F. and O.M.Y.) independently retrieved and screened all studies according to these predetermined selection criteria. In addition, we manually screened references in the selected articles for additional relevant studies. Initial selection was based on title and abstract screening, and final selection was performed using full texts. Exclusion criteria were ineligible study design (eg, interventional study for management of MOP or GWG or for prevention of childhood asthma or wheeze), ineligible population (eg, adults), ineligible outcomes (eg, other than childhood asthma or wheeze), and insufficient information in English to determine inclusion criteria and abstract risk estimates. Differences of opinion for inclusion were resolved by discussion.

Data Extraction and Quality Assessment

Using a uniform data extraction form, 2 of the authors (E.F. and O.M.Y.) independently extracted from full-text articles all data on references (first author, year of publication), number of participants, timing of MOP or GWG determination (eg, gestational age at which “final” maternal weight was
ascertained), BMI or GWG (means or categories) as reported by the original studies, outcome definitions, ages at which outcomes were measured, total number of participants, number of participants with and without the outcomes when available, odds ratios (ORs) or risk ratios with their corresponding confidence intervals (CIs), and relevant covariates as reported in the original studies (eg, mean maternal age, race, smoking exposure during pregnancy or childhood). Disagreements on data extraction between the 2 authors were resolved through mutual discussion and, if needed, consultation with a third author (J.C.C.). Agreement between the reviewers on study selection was determined by using the Cohen $k$ statistic ($k$). The quality of reporting in the included studies was assessed by using the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement checklist. Studies were graded as A (>85% of STROBE criteria fulfilled), B (50–85%), or C (<50%).

**Analysis**

Data collected were pooled to generate summary estimates; each study was weighed by its inverse effect size variant. To evaluate the association of MOP or GWG, we calculated ORs for the development of childhood asthma or wheeze. Many studies provided different categories for MOP and GWG; therefore, when possible we contacted the corresponding authors of the original studies to provide us with estimates for BMI and GWG (in kilograms) or kindly responded that continuous data were.

**RESULTS**

A total of 474 studies were identified (Fig 1): 398 from PubMed, 31 from Embase, 28 from Scopus, 7 from Cumulative Index to Nursing and Allied Health Literature, 1 from the Cochrane Database, and 9 from Ovid; no additional references were identified from reviewing references in relevant articles. Of these, 14 studies with a total of 108,321 mother–child pairs were included in the meta-analysis (Table 1). There was complete agreement on 469 of 474 articles after title and abstract screening (interreader agreement $\kappa = .90$) and on 40 of 42 articles after full-text screening ($\kappa = .89$).

**Characteristics of Included Studies**

Included studies were published between March 1996 and October 2013. Twelve studies reported maternal BMI (continuous or categorical) closely before or at the beginning of pregnancy and were included in the analysis of MOP; 5 studies were included in the analysis of GWG. Although many studies categorized MOP and GWG in different ways, response from the authors of the original studies was very positive, and the majority of them provided us with estimates for continuous BMI and GWG (in kilograms) or kindly responded that continuous data were.

![Flowchart of study selection](image)
<table>
<thead>
<tr>
<th>Reference</th>
<th>N</th>
<th>Age of Children at Outcome</th>
<th>City or Country</th>
<th>Ascertainment of Exposure, Outcome</th>
<th>Risk Estimates as Originally Reported</th>
<th>Comments</th>
<th>Quality Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Caudri et al 2013</td>
<td>3963</td>
<td>8 y</td>
<td>Netherlands</td>
<td>Self-report; self-report</td>
<td>Persistent wheeze: Continuous prepregnancy BMI, OR = 1.26 (CI, 1.01–1.57).</td>
<td>Adjusted for gender, parental allergy, smoke exposure, breastfeeding, day care, pregnancy duration, older siblings, birth wt, maternal age, study region, parental education, and maternal asthma.</td>
<td>A</td>
</tr>
<tr>
<td>Guerra et al 2013</td>
<td>1107</td>
<td>14 mo</td>
<td>Spain</td>
<td>Self-report</td>
<td>Frequent wheeze: Continuous BMI, OR = 1.08 (CI, 1.01–1.15). BMI categories: BMI &lt;18.5, OR = 1.7 (CI, 0.3–8.3); BMI 25–30, OR = 1.0 (CI, 0.4–2.6); BMI &gt;30, OR = 4.2 (CI, 1.5–11.3).</td>
<td>Adjusted for maternal socioeconomic status, child's gender and wt for length, type of delivery, preterm birth, birth wt, day care, breastfeeding, maternal age, parity, and smoking, and parental asthma.</td>
<td>A</td>
</tr>
<tr>
<td>Håberg et al 2009</td>
<td>32</td>
<td>18 mo</td>
<td>Norway</td>
<td>Self-report; self-report</td>
<td>Wheeze: BMI categories: BMI 25–30, RD = 0.4 (CI, –1.1, 1.8); BMI &gt;30, RD = 3.3 (CI, 1.2, 5.3).</td>
<td>Adjusted for maternal age, parity, education, income, asthma, and smoking in pregnancy, parental smoking after birth, breastfeeding, day care, child's gender, low birth wt, preterm birth, and cesarean section. Continuous data obtained directly from the author.</td>
<td>A</td>
</tr>
<tr>
<td>Halonen et al 2013</td>
<td>261</td>
<td>9 y</td>
<td>United States (Tucson, AZ)</td>
<td>Medical records, measured</td>
<td>Asthma: Prepregnancy BMI tertiles: Middle tertile OR = 0.5 (CI, 0.2–1.3); high OR = 0.4 (CI, 0.2–1.1). GWG categories: High GWG, OR = 3.4 (CI, 1.6–7.2).</td>
<td>Adjusted for maternal age, ethnicity, and parity, parental smoking, and child's gender. Continuous data obtained directly from the author.</td>
<td>A</td>
</tr>
<tr>
<td>Harpsøe et al 2013</td>
<td>38</td>
<td>7 y</td>
<td>Denmark</td>
<td>Self-report; self-report</td>
<td>Asthma ever: BMI categories: BMI &lt;18.5, OR = 1.03 (CI, 0.88–1.22); BMI 25–30, OR = 1.22 (CI, 1.12–1.33); BMI 30–35, OR = 1.56 (CI, 1.36–1.79); BMI &gt;35, OR = 1.55 (CI, 1.23–1.95). GWG categories: &lt;5 kg, OR = 1.17 (CI, 0.96–1.45); 5–9 kg, OR = 1.02 (CI, 0.91–1.15); 10–14 kg, OR = 0.97 (CI, 0.89–1.06); 15–19 kg, OR = 1.15 (CI, 1.05–1.27); ≥20 kg, OR = 1.19 (CI, 1.04–1.35).</td>
<td>Adjusted for maternal age, race, socioeconomic status, smoking during pregnancy, atopy, day care use, atopy, cesarean delivery, child gender, and number of siblings. Continuous data obtained directly from the author.</td>
<td>A</td>
</tr>
<tr>
<td>Reference</td>
<td>N</td>
<td>Age of Children at Outcome</td>
<td>City or Country</td>
<td>Ascertainment of Exposure; Outcome</td>
<td>Risk Estimates as Originally Reported</td>
<td>Comments</td>
<td>Quality Score</td>
</tr>
<tr>
<td>--------------------------</td>
<td>-----</td>
<td>---------------------------</td>
<td>-----------------</td>
<td>-----------------------------------</td>
<td>-------------------------------------</td>
<td>---------------------------------------------------------------------------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Kumar et al 2010&lt;sup&gt;22&lt;/sup&gt;</td>
<td>1191</td>
<td>3 y</td>
<td>United States (Boston, MA)</td>
<td>Self-report</td>
<td>Recurrent wheezing: BMI categories: BMI 25–30, OR = 1.58 (CI, 0.75–3.30); BMI &gt;30, OR = 3.51 (CI, 1.88–7.32).</td>
<td>Adjusted for maternal age, race, education, atopy, child's gender, premature delivery, smoking during pregnancy and at home, fetal growth retardation, and large size for gestational age. Continuous data obtained directly from the author.</td>
<td>A</td>
</tr>
<tr>
<td>Leermakers et al 2013&lt;sup&gt;33&lt;/sup&gt;</td>
<td>4656</td>
<td>4 y</td>
<td>Netherlands</td>
<td>Self-report; measured</td>
<td>Current wheeze: No family history: Continuous BMI, OR = 1.02 (CI, 0.98–1.08). Categories: BMI &lt;20, OR = 0.93 (CI, 0.79–1.09); BMI 25–30, OR = 1.09 (CI, 0.95–1.26); BMI &gt;30, OR = 0.93 (CI, 0.73–1.19).</td>
<td>Study included 2 subgroups. Adjusted for maternal age, parity, ethnicity, education, smoking during pregnancy, pets, gestational complications, gestational age at measurement, child's gender, gestational age at birth, birth wt, breastfeeding, day care, and child's height and wt at follow-up. Continuous data obtained directly from the author.</td>
<td>A</td>
</tr>
<tr>
<td>Oliveti et al 1996&lt;sup&gt;24&lt;/sup&gt;</td>
<td>262</td>
<td>4–9 y</td>
<td>United States (Cleveland, OH)</td>
<td>Medical records</td>
<td>Asthma: GWG category (&lt;9 kg): OR = 3.42 (CI, 1.72–6.79).</td>
<td>Adjusted for maternal asthma history, bronchiolitis, maternal smoking, lack of prenatal care, use of oxygen at birth, prematurity, low birth wt ≤2500 g, and 5-min Apgar score.</td>
<td>B</td>
</tr>
<tr>
<td>Patel et al 2012&lt;sup&gt;25&lt;/sup&gt;</td>
<td>6945</td>
<td>15–16 y</td>
<td>Northern Finland</td>
<td>Medical records</td>
<td>Wheeze ever: BMI categories for wheeze (ever) or asthma (ever): BMI &lt;18.5, OR = 0.80 (CI, 0.58–1.09); BMI 25–30, OR = 1.18 (CI, 0.95–1.47); BMI &lt;30, OR = 0.99 (CI, 0.86–1.18). Continuous BMI, OR = 1.028 (CI, 1.005–1.051).</td>
<td>Adjusted for socioeconomic status, marital status, maternal education, maternal asthma, birth wt, parental smoking during gestation, and adolescent BMI at age 15 y.</td>
<td>A</td>
</tr>
<tr>
<td>Pike et al 2013&lt;sup&gt;26&lt;/sup&gt;</td>
<td>940</td>
<td>6 y</td>
<td>United Kingdom</td>
<td>Measured</td>
<td>Continuous BMI: Asthma ever: OR = 1.06 (CI, 0.91–1.24). Current asthma: OR = 1.10 (CI, 0.92–1.32). Wheeze ever: OR = 1.08 (CI, 1.02–1.13). Current wheeze: OR = 1.02 (CI, 0.87–1.20).</td>
<td>Adjusted for maternal education, asthma, smoking in pregnancy, parity, child's gender, birth wt, breastfeeding, and other outcome-specific covariates.</td>
<td>A</td>
</tr>
</tbody>
</table>
For prepregnancy BMI, 7 studies used maternal self-report of height or weight,16–18,21,22–23,29 and 5 used medical records or directly measured both.20,25–27,30 For GWG, 4 studies used the difference between weight in the third trimester and that in the first trimester, and 1 used self-report.17,22,24,28 Outcomes reported varied and included wheezing (ever, current, transient, or persistent) and asthma (ever or current); 12 studies used self-report (of which 3 studies specified "report of physician-diagnosed asthma")20,21,27,29,30 and 2 studies reported using physician diagnosis or medical record review.22,24 For comparability purposes, we grouped (when possible) the outcomes into 2 broader categories: "asthma/wheeze ever"17,18,20–22,25–30 and "current asthma/wheeze."21,23–26,29

Table 1 shows characteristics of individual studies, including outcome, obesity categories, and ORs as defined and reported in the original manuscript, as well as reported covariates used in their adjusted models. 

Table shows characteristics of individual studies, including outcome, obesity categories, and ORs as defined and reported in the original manuscript, as well as reported covariates used in their adjusted models. 

A Quality of reporting assessment based on STROBE statement criteria.19
was not associated with asthma or wheeze ($P = .71$).

Figure 3 shows the pooled analysis of maternal BMI and asthma or wheeze. In this analysis, maternal BMI was significantly associated with higher odds of asthma or wheeze (OR = 1.03 per each 1 kg/m² increase; 95% CI, 1.02–1.05; $P < .001$) and current asthma or wheeze (OR = 1.02 per kg/m²; 95% CI, 1.01–1.04; $P = .009$). There was significant heterogeneity for both outcomes (asthma or wheeze ever, $I^2 = 70.4$%; current asthma or wheeze, $I^2 = 66.3$%). The Egger test showed there could be significant publication bias for asthma or wheeze ever ($P = .04$) but not for current asthma or wheeze ($P = .99$).

**Gestational Weight Gain**

Table 1 shows the original studies with GWG as reported (categories or continuous). Figure 4 shows the pooled
analysis by reported GWG categories. Children whose mothers were in the higher GWG categories had significantly higher odds of asthma or wheeze ever (OR = 1.16; 95% CI, 1.001–1.34; \( P = .049 \)) but not of current asthma or wheeze (OR = 1.08; 95% CI, 0.89–1.31; \( P = .45 \)). Figure 5 shows the pooled analysis of maternal (continuous) GWG and asthma or wheeze. In this analysis, maternal GWG was significantly associated with higher odds of current asthma or wheeze (OR = 1.015 per 1-kg increase in GWG; 95% CI, 1.001–1.02; \( P < .001 \)) but not with asthma or wheeze ever (OR = 1.04 per kg; 95% CI, 0.97–1.11; \( P = .27 \)). Both for GWG categories and for continuous GWG, the number of studies was small \( (n = 2–3) \). The Egger test showed no significant evidence of publication bias for current asthma or wheeze \( (P = .52) \), but it could not be calculated for asthma or wheeze ever because of the small number of studies. Subnormal GWG was not associated with asthma or wheeze \( (P = .19) \); Supplemental Figure 7), but the number of studies reporting was small \( (n = 3) \).

### Subgroup Analysis and Meta-regression

Meta-regression was performed for BMI with covariates available for extraction from the original studies (at the study level [eg, mean or median maternal age in the study] or at the category level when available [eg, mean or median maternal age within each BMI category in the study]). For continuous BMI, meta-regression showed a negative association of borderline significance between maternal history of asthma and the study effect size: The risk of childhood asthma or wheeze with increasing maternal BMI was higher when the prevalence of maternal asthma was lower \( (\beta = 0.90; 95\% \text{ CI}, 0.80–1.01; P = .07) \); this effect modification explained part of the study heterogeneity \( (\hat{I}^2 \text{ decreased to } 33.6\%; \text{ R}^2 = 81.5\%) \). We were unable to perform subgroup analysis or meta-regression for GWG because of the small number of studies.

### DISCUSSION

In this meta-analysis, we report that children whose mothers were obese during pregnancy (defined by BMI categories or by higher continuous BMI) are at higher risk of asthma or wheeze. Maternal underweight did not appear to increase the risk of asthma or wheeze in childhood, although this analysis included only a few studies with small sample sizes and may have been underpowered.

Maternal obesity could influence the risk of asthma in the offspring through several mechanisms. Obesity is associated with a chronic, low-grade inflammatory state. For example, it has been associated with elevated levels of inflammatory cytokines implicated in asthma, such as tumor necrosis factor \( \alpha \) (TNF-\( \alpha \)), interleukin 6, and transforming growth factor \( \beta \)-1. Leptin, a proinflammatory adipokine, not only is elevated in the maternal circulation of pregnant obese women but also is higher in the cord blood of their children than in children whose mothers are not obese. Conversely, adiponectin, which has antiinflammatory properties and has shown inverse associations with asthma symptoms and airway inflammation, is decreased in obesity and is also decreased in newborns of obese mothers. Alternatively, maternal obesity may influence the pathogenesis of asthma through exposure of the developing fetus to different dietary patterns. For example, obese women are more likely to have low serum levels of vitamin D, and maternal vitamin D insufficiency or deficiency has been associated with elevated risk of childhood asthma. Similarly, maternal consumption of other foods during pregnancy (eg, meat, dairy, or fats) has
been associated with childhood asthma. Finally, shared genetic polymorphisms or epigenetic changes as a result of maternal obesity could be causing, mediating, or modifying the elevated risk of asthma in their offspring.

Individual studies assessing whether maternal history of asthma modifies the effect of MOP on childhood asthma have shown conflicting results. In our meta-regression analysis, there was significant modification of the effect of MOP on asthma by maternal asthma: There was a more pronounced increase in the risk of childhood asthma when the prevalence of maternal asthma was lower. Although such analysis is only exploratory and should be interpreted with caution, it could indicate that the risk conferred by the mother’s asthma supersedes that conferred by maternal obesity. The heritability of asthma has been estimated to be \( \sim 0.82-0.91 \) and studies with higher prevalence of maternal asthma could be underpowered to detect an effect of maternal obesity. Alternatively, this finding may suggest that the risk from maternal obesity is stronger for nonatopic asthma. Many but not all studies of obesity and asthma have reported this association to be stronger among nonatopic children or adults. GWG was reported in fewer studies. Although there seems to be a higher risk of asthma or wheeze with higher GWG, the observed associations varied depending on the way the exposure was reported (categorical or continuous GWG) and the definition of asthma or wheeze. GWG has also been associated with elevated maternal and cord blood leptin levels. Halonen et al reported that persistently elevated TNF-\( \alpha \) from birth to 3 months of age was associated with asthma and decreased lung function at age 9 years and that maternal GWG was the strongest predictor of an elevated TNF-\( \alpha \) level. These findings suggest that GWG and maternal obesity may contribute to the onset of childhood asthma via similar proinflammatory mechanisms. Additional studies are needed to reach more definitive conclusions in regard to GWG and childhood asthma or wheeze.

Studies addressing maternal obesity and childhood asthma that did not meet inclusion criteria for our meta-analysis should be mentioned. In a Swedish
cohort of ∼431,000 first-born children, Lowe et al\(^4\) reported that MOP was associated with greater use of inhaled corticosteroid use in boys and girls up to age 12 years and in girls up to age 16 years; these results suggest that MOP may also be a risk factor for more severe or persistent childhood asthma. Furthermore, in a study by Watson and McDonald,\(^4\) both maternal baseline skinfold thickness (as a surrogate of percentage body fat) and increase in skinfold thickness during pregnancy were independently associated with greater risk of asthma in childhood, whereas BMI was not significant. The authors proposed that skinfold measurement may be more sensitive than BMI; this extends to maternal obesity in our recent report that for studies of asthma, the child’s BMI may not be the best or sole indicator of adiposity.\(^4\)

The current study has several limitations. We included only articles published in English or with sufficient information in English to abstract data for analysis, which may not fully represent all studies conducted on the subject. There was high variability among studies. We dealt with this variability in 3 ways: To account for effect size variability, we used random effects models; to account for the variability in the way BMI and GWG were categorized in the original studies, we obtained effect sizes using continuous BMI or GWG from many of the authors of the original reports; and we performed meta-regression analyses to detect significant effect modifiers. However, as with any meta-analysis, we were limited to the covariates available to us from the original articles. Finally, maternal obesity is also a risk factor for childhood obesity, and the elevated risk of asthma could result partly from the child’s own obesity; however, such confounding is unlikely given that most of the included studies adjusted for birth weight\(^1,16,17,22,25,26,28,30\) or for the child’s weight or BMI at the time of assessment of the outcome.\(^17,23,25,27,29\)

**CONCLUSIONS**

We report that MOP is a significant risk factor for the development of childhood asthma or wheeze. GWG may also increase the risk of childhood asthma or wheeze, but we were limited by the small number of studies. The effect of maternal obesity on childhood asthma may be more pronounced when the prevalence of maternal asthma is lower.

---

### FIGURE 5

Pooled analysis by continuous GWG and asthma or wheeze. Increasing GWG (in kg) was significantly associated with current asthma or wheeze but not with asthma or wheeze ever (\(P = .27\)) during childhood. Note that ORs are for each 1-kg increase in GWG. Note the small number of studies in each outcome (\(n = 2\)).

<table>
<thead>
<tr>
<th>Study ID</th>
<th>OR (95% CI)</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthma/Wheeze (ever)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Harpsøe 2012</td>
<td>1.01 (1.00–1.01)</td>
<td>59.83</td>
</tr>
<tr>
<td>Halonen 2013</td>
<td>1.08 (1.02–1.15)</td>
<td>40.17</td>
</tr>
<tr>
<td>Subtotal ((P = 80.1%), (p = .025))</td>
<td>1.04 (0.97–1.11)</td>
<td>100.00</td>
</tr>
<tr>
<td>Asthma/Wheeze (current)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Harpsøe 2012</td>
<td>1.01 (1.00–1.02)</td>
<td>47.83</td>
</tr>
<tr>
<td>Leermakers 2013</td>
<td>1.02 (1.00–1.03)</td>
<td>19.93</td>
</tr>
<tr>
<td>Leermakers 2013</td>
<td>1.02 (1.01–1.03)</td>
<td>32.24</td>
</tr>
<tr>
<td>Subtotal ((P = 0.0%), (p = .453))</td>
<td>1.01 (1.01–1.02)</td>
<td>100.00</td>
</tr>
</tbody>
</table>


41. van Beijsterveldt CE, Boomsma DI. Genetics of parentally reported asthma, eczema and rhinitis in 5-yr-old twins. *Eur Respir J.* 2007;29(5):516–521


44. Telenga ED, Tideman SW, Kerstjens HA, et al. Obesity in asthma: more neutrophilic inflammation as a possible explanation for a reduced treatment response. *Allergy.* 2012;67(8):1060–1068


49. Watson PE, McDonald BW. Subcutaneous body fat in pregnant New Zealand women: association with wheeze in their infants at 18 months. *Matern Child Health J.* 2013;17(5):959–967


(Continued from first page)

**FINANCIAL DISCLOSURE:** The authors have indicated they have no financial relationships relevant to this article to disclose.

**FUNDING:** Dr Forno was supported by NIH grant K12-HD052892. Dr Celedón was supported by NIH grants HL079966 and HL117191 and an endowment from the Heinz Foundation. Funded by the National Institutes of Health (NIH).

**POTENTIAL CONFLICT OF INTEREST:** Dr Celedón served as a one-time consultant for Genentech in 2011 on an issue unrelated to this manuscript; the other authors have indicated they have no potential conflicts of interest to disclose.
Maternal Obesity in Pregnancy, Gestational Weight Gain, and Risk of Childhood Asthma
Erick Forno, Omar M. Young, Rajesh Kumar, Hyagriv Simhan and Juan C. Celedón

Pediatrics 2014;134:e535; originally published online July 21, 2014;
DOI: 10.1542/peds.2014-0439

The online version of this article, along with updated information and services, is located on the World Wide Web at:
/content/134/2/e535.full.html